Vivace Therapeutics Strengthens Leadership Team as It Prepares to Advance VT3989, the First TEAD Inhibitor to enter Phase 3 Clinical Trials, as the Leading Treatment for Mesothelioma

Phase 3VT3989Positive

AI Analysis

Summary

Vivace Therapeutics strengthens its leadership team with new President and CEO Craig Gibbs, Chief Business and Strategy Officer Ellen Lubman, and board member Tim Clackson as it advances VT3989, the first TEAD inhibitor entering Phase 3 trials for mesothelioma, following FDA Safe to Proceed clearance for the pivotal sTEADfast study.

Clinical Trial Data

Phase

Phase 3

Outcome Details

FDA grants Safe to Proceed for pivotal Phase 3 sTEADfast clinical study

Importance:7/10

Sentiment:

0.80

LeadershipPhase 3TEAD InhibitorMesotheliomaFDA ClearanceManagement Appointment

Related Companies

$INTI $DFPH $TRAX

Read the original article

Published by PR Newswire Biotech on August 26, 2026 11:00 AM

Read Original